🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

59 results for “venetoclax” Clear

  1. AZACITIDINE, Venetoclax, Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  2. Azacitidine Combined With Venetoclax and ATRA group

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  3. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  4. Imnovid 3 mg hard capsules, DEXAMETHASONE , Venetoclax, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    R/R Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. Intermediate-dose Cytarabine in Combination with Venetoclax

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  6. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  7. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  8. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Pharma Mar S.A.

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  9. Venetoclax

    China SXT Pharmaceuticals

    AML

    phase 3 small molecule active

    2 trials

  10. Venetoclax

    China SXT Pharmaceuticals

    Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  11. Venetoclax

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  12. Venetoclax 400

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  13. Venetoclax in combination with fludarabine and melphalan

    First Tracks Biotherapeutics

    Venentoclax

    phase 3 small molecule active

    1 trial

  14. Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial

  15. Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  16. Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  17. Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  18. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  19. venetoclax

    First Tracks Biotherapeutics

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  20. Avapritinib, azacitidine, Venetoclax

    China SXT Pharmaceuticals

    AML (Acute Myelogenous Leukemia)

    phase 2 small molecule active

    1 trial

  21. Azacitidine in Combination With Venetoclax

    First Tracks Biotherapeutics

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  22. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    China SXT Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  23. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    China SXT Pharmaceuticals

    Relapsed/Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  24. BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources